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Objective: Fibrinogen plays a key role in the pathogenesis of atherosclerosis and complications of atherothrombotic disease.
We investigated the prognostic impact of fibrinogen levels on mortality of high risk patients with peripheral artery disease
(PAD).
Methods: We studied 486 patients with PAD and several cardiovascular comorbidities. Atherosclerotic risk factors and
fibrinogen levels were determined at initial presentation and patients were followed for median 7 years (IQR 6–10) for all-
cause and cardiovascular mortality. Multivariate Cox regression analysis was applied to assess the predictive value of
fibrinogen levels (in quartiles) on patients’ outcome.
Results: Cumulative survival rates at 1, 3, 5 and 10 years were 96, 91, 83 and 67%, respectively. Overall, 138 patients
(28%) died, 70% of these patients died of cardiovascular complications (n ¼ 96). Patients with fibrinogen levels 10.2–
12.2 mmol/l (third quartile) and patients with fibrinogen levels above 12.2 mmol/l (fourth quartile) had a significantly
increased adjusted risk for all-cause mortality (hazard ratios [HR] 1.87 and 1.90, p ¼ 0.025 and p ¼ 0.020, respectively)
compared to patients in the lowest quartile (fibrinogen below 8.6 mmol/l). A consistent effect was observed for cardiovascular
causes of death. Diabetes mellitus and critical limb ischemia were the only other independent predictor variables (HR 2.08,
p , 0.001 and 1.88, p ¼ 0.001, respectively).
Conclusion: Elevated fibrinogen levels in high risk patients with PAD indicate an increased risk for poor outcome,
particularly for fatal cardiovascular complications.
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Introduction
Complications of atherosclerosis are the most common
causes of death in Western societies.1 Although
atherosclerosis was formerly considered a bland
lipid storage disease, substantial advances in basic
and experimental science have illuminated the role of
inflammation and the underlying cellular and mol-
ecular mechanisms that contribute to atherogenesis.1,2
Compelling evidence for the importance of inflam-
mation and atherosclerosis at both the basic and
clinical level has evolved in parallel. Accumulating
data indicate that insights gained from the link
between inflammation and atherosclerosis can yield
predictive and prognostic information of considerable
clinical utility.3 In broad outline, atherosclerosis can be
considered to be a form of chronic inflammation
resulting from interaction between modified lipopro-
teins, monocyte-derived macrophages, T-cells, and the
normal cellular elements of the arterial wall.4 This
inflammatory process can ultimately lead to the
development of complex lesions, or plaques, that
protrude into the arterial lumen.1 Plaque rupture and
thrombosis may result in the clinical complications of
stroke or myocardial infarction.4
Fibrinogen is essential for fibrin formation under
the influence of thrombin, and forms the basic plug of
plasmatic coagulation and platelet aggregation.5,6
Furthermore, fibrinogen synthesis is stimulated by
cytokines from activated megacaryocytes thus acting
as an acute phase reactant and a mediator of
inflammatory processes. In particular, it is a ligand
for cellular integrins and increases the binding of
platelets, endothelial cells and leukocytes to each other
which in turn causes activation of leukocytes and
platelets, and release of mediators from these cells.7,8
Fibrinogen, therefore, can be considered as a key
molecule in the cascades of inflammation and coagu-
lation and supposedly is involved in the pathogenesis
of atherosclerosis and occurrence of atherothrombotic
complications.9,10 Recently, fibrinogen was described
as a risk factor particularly for the development of
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peripheral artery disease (PAD)11 and was suggested
to be associated with an increased risk of short-term
mortality.12 However, the predictive value of fibrino-
gen on the long-term outcome of high risk patients
with PAD has not been assessed as yet.
We hypothesized that elevated fibrinogen levels
would be associated with an increased risk of long
term mortality in patients with pre-existing, severe
atherosclerosis. Therefore, the aim of the present study
was to investigate the prognostic impact of fibrinogen
on 10 year all-cause and cardiovascular mortality of
high risk patients with PAD.
Methods
Study design, inclusion and exclusion criteria
We analyzed the data of all inpatients with sympto-
matic PAD Fontaine stages IIa, IIb, III and IV who were
admitted to the Angiology department of a tertiary
care university hospital from January 1, 1990 to
December 31, 1992. PAD was assessed by clinical
evaluation, ankle brachial index measurements,
duplex sonography and confirmed by lower limb
angiography in all patients. Patients were identified
using our registry database, which prospectively
recorded these patients’ data. Furthermore, data
were completed by systematic chart review. The
main outcome measure was mortality until December
31, 1999. The study complied with the Declaration of
Helsinki.
Definitions
Diabetes mellitus was defined as fasting blood glucose
levels above 110 mg/dl measured at three different
occasions, pathologic oral glucose tolerance tests and
glycated hemoglobin (HbA1c) .6.0%. Hyperlipide-
mia was defined as fasting total serum cholesterol
.200 mg/dl, LDL cholesterol .130 mg/dl or serum
triglycerides .180 mg/dl and was assumed to be
present in all patients on lipid lowering medication.
Arterial hypertension was defined as blood pressure
values above 140/90 mmHg in repetitive measure-
ments and was considered to be present in all patients
with a history of hypertension taking anti-hyperten-
sive medication.
Patient data
At admission patients medical history and data from
physical examination were recorded using a standard
questionnaire. Laboratory examination included com-
plete blood count, global coagulation tests, HbA1c,
total cholesterol, LDL cholesterol, HDL cholesterol,
lipoprotein (a), and serum uric acid. Clinical history
and physical examination were evaluated with special
attention to cardiovascular risk factors and comorbid-
ities: age, gender, hyperlipidemia, hypertension, dia-
betes mellitus, coronary artery disease, history of
cerebrovascular events, current medication, and
smoking habits at the time of admission in categories
(non-smoker, 1–9 cigarettes daily, 10–19 cigarettes
daily, 20 or more cigarettes daily).
Laboratory investigations
For measurement of fibrinogen Fibrinogen Claussw
(Stago, Roche) with a sensitivity of 0.6 mmol/l, a
normal range of 4.4–10.3 mmol/l, and a coefficient of
variation of 5.2% was used, since the automated
Clauss assay has been established as the standard for
measurement of fibrinogen.13
Follow-up
Patients were followed for case fatality until December
31, 1999. The Austrian Central Statistical Office
provided data of patients who died within that period
(day and cause of death, ICD 9).
Statistical analysis
Continuous data are presented as the median and the
interquartile range (IQR, range from the 25th to the
75th percentile). Discrete data are given as counts and
percentages. The Chi-square test was used to compare
proportions and the Mann–Whitney U Test was
applied for univariate comparison of continuous
data. Mortality rates according to the fibrinogen level
(in quartiles) are presented as a Kaplan–Meier curve
and compared by means of the Log Rank test.
Multivariate Cox regression analysis was applied to
assess the independent effect of fibrinogen on all-cause
and cardiovascular mortality, and to adjust for
confounding effects of other atherosclerotic risk
factors. Results of the Cox logistic regression model
were presented as the hazard ratio (HR) and the 95%
confidence interval (95% CI). Multiplicative inter-
action terms and log likelihood ratio Chi-square tests
were used to test for interactions between predictor
variables. A two sided p-value ,0.05 was considered
as statistically significant. All calculations were
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performed with SPSS for Windows (Version 10.0, SPSS
Inc, Chicago, IL, USA).
Results
We included 486 patients with PAD in the present
analysis. The median age was 72 years (IQR 64–79),
and 296 patients were male (61%). Fibrinogen values at
the time of initial presentation were median
10.2 mmol/l (IQR 8.6–12.2). According to the reference
values of our laboratory, 256 patients (53%) had a
normal fibrinogen level (4.4 – 10.3 mmol/l), 228
patients (47%) had an elevated fibrinogen level
(.10.3 mmol/l) and two patients (0.4%) had a lower
than normal fibrinogen (,4.4 mmol/l).
Mortality
The median follow-up period was 89 months (i.e. 7.3
years) (IQR 72–119 months). Cumulative survival
rates at 1, 3, 5 and 10 years were 96, 91, 83 and 67%,
respectively. During the follow-up period until
December 31, 1999, overall 138 patients (28%) died.
Median survival time in non-survivors was 67 months
(i.e. 5.5 years) (IQR 39 – 93 months). We found
predominately cardiovascular causes of death (myo-
cardial infarction and stroke) in these patients (96 of
138, 70%). Twenty-three patients (17%) died because of
carcinomas, the remaining 19 patients (14%) died
following traumas, infectious diseases and respiratory
insufficiency due to chronic obstructive pulmonary
diseases and renal insufficiency. Demographic data
and clinical characteristics of survivors and non-
survivors are given in Table 1. Non-survivors were
older, had more frequently diabetes mellitus, arterial
hypertension and critical limb ischemia.
Fibrinogen and mortality
Fibrinogen values were divided into quartiles to
analyze its potential impact on patients’ outcome.
Compared to patients in the lowest quartile (n ¼ 122;
fibrinogen ,8.6 mmol/l), patients in the second
(n ¼ 121; fibrinogen 8.6–10.2 mmol/l), third (n ¼ 122;
fibrinogen 10.2–12.2 mmol/l) and fourth quartile
(n ¼ 121; fibrinogen .12.2 mmol/l) had a cumulat-
ively increasing risk for mortality (p ¼ 0:0014; Fig. 1).
We then applied a multivariate Cox proportional
hazard model to assess the independent effect of
fibrinogen on all-cause mortality and adjust for the
confounding effects of other baseline variables.
Patients in the third and fourth quartile of fibrinogen
values had a significantly increased adjusted risk for
mortality compared to patients in the lowest quartile
(Table 2). The final model adjusted for age (in
quartiles), sex, smoking (in categories), diabetes
mellitus, hyperlipidemia, arterial hypertension and
critical limb ischemia (vs. intermittent claudication).
Although patients with diabetes mellitus showed
significantly higher fibrinogen values compared to
non-diabetic patients ðp ¼ 0:001Þ; we observed no
significant interaction between fibrinogen and dia-
betes or any other baseline variable, indicating that
fibrinogen is an independent predictor of mortality in
these patients. In particular, we found no significant
interaction between fibrinogen, smoking habits and
death, and there were no significant differences of
fibrinogen levels between non-smokers and smokers
(in categories) ðp ¼ 0:47Þ: Diabetes mellitus and critical
Table 1. Demographic data and clinical characteristics of 486 patients presenting with peripheral artery disease: comparing long-term
survivors and non-survivors.
Survivors (n ¼ 348; 72%) Non-survivors (n ¼ 138; 28%) p-value
Age (years) 71 (61–79) 74 (69–80) ,0.001
Male sex 212 (61%) 84 (61%) 0.99
Smoking at admission 0.16
Non-smoker 140 (40%) 70 (51%)
1–9 cigarettes daily 128 (37%) 44 (32%)
10–19 cigarettes daily 46 (13%) 16 (12%)
20 or more cigarettes daily 34 (10) 8 (6%)
Diabetes mellitus 102 (29%) 76 (55%) ,0.001
Arterial hypertension 147 (42%) 77 (56%) 0.007
Hyperlipidemia 301 (87%) 110 (80%) 0.062
Critical limb ischemia 62 (18%) 45 (33%) ,0.001
Coronary artery disease 176 (51%) 69 (50%) 0.97
History of myocardial infarction 54 (16%) 29 (21%) 0.57
History of stroke 17 (5%) 7 (5%) 0.93
Continuous data are given as median and interquartile range (range from the 25th to the 75th percentile).
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limb ischemia were the only other independent
predictors of death in these patients.
Assessing the risk for cardiovascular death accord-
ing to patients’ baseline fibrinogen level, we found
that patients in the second (adjusted HR 1.99, 95% CI
1.07–4.08, p ¼ 0:031), third (adjusted HR 2.66, 95% CI
1.37–5.10, p ¼ 0:007) and fourth quartile (adjusted HR
2.68, 95% CI 1.39–5.16, p ¼ 0:003) had an increased
risk for poor outcome compared to patients in the
lowest quartile of fibrinogen levels, adjusting for age
(in quartiles), sex, smoking (in categories), diabetes
mellitus, hyperlipidemia, and arterial hypertension
and critical limb ischemia.
Discussion
We found that higher fibrinogen levels were associated
with a significantly increased risk for 10-year-mor-
tality in patients with PAD. Particularly, fatal cardio-
vascular complications frequently occurred in these
patients. This association was independent of any
other atherothrombotic risk factor.
Fig. 1. Cumulative mortality of 486 patients with peripheral artery disease according to the fibrinogen level at initial
presentation.
Table 2. Cox proportional hazard model to assess the predictive value of fibrinogen on 10 year mortality of patients with peripheral artery
disease adjusting for confounding factors.
Hazard ratio 95% Confidence interval p- value
Fibrinogen
First quartile (,8.6 mmol/l) 1.0 – –
Second quartile (8.6–10.2 mmol/l) 1.47 0.85–2.56 0.17
Third quartile (10.2–12.2 mmol/l) 1.87 1.09–3.23 0.025
Fourth quartile (.12.2 mmol/l) 1.90 1.11–3.41 0.020
Male sex 1.22 0.85–1.76 0.31
Age (in quartiles) 1.17 0.97–1.38 0.13
Smoking (in categories)
Non-smoking 1.0 – –
1–9 cigarettes daily 1.22 0.77–1.93 0.40
10–19 cigarettes daily 1.22 0.65–2.27 0.53
20 or more cigarettes daily 0.80 0.35–1.80 0.58
Hyperlipidemia 0.80 0.45–1.17 0.18
Diabetes mellitus 2.25 1.51–3.36 ,0.001
Arterial hypertension 1.30 0.89–1.90 0.17
Critical limb ischemia 1.88 1.30–2.74 0.001
L. Doweik et al.384
Eur J Vasc Endovasc Surg Vol 26, October 2003
Atherosclerosis has been demonstrated to be related
to an inflammatory process in the vascular wall.2,3,14,15
The activity of the disease and the likelihood of its
progression are influenced by the extent of the
vascular inflammatory process.14,15 In this context, a
close association between atherosclerosis and
increased levels of fibrinogen have been described,16,17
presumably indicating underlying vascular inflam-
mation. Fibrinogen is a marker of acute phase
response and provides an indirect measure of a
cytokine dependent inflammatory process of the
arterial wall. The molecule is a ligand for cellular
integrins and increases the binding of platelets,
endothelial cells and leukocytes to each other which
in turn causes activation of leukocytes and platelets,
and release of mediators from these cells.7,8 Further-
more, fibrinogen plays a key role in the coagulation
cascade serving as a ligand for the platelet GPIIb/IIIa
receptor. Such a pivotal role in platelet physiology and
development of arterial thrombosis parallels the
consistency of clinical studies, which showed an
increased cardiovascular risk for elevated fibrinogen
levels.9,10,12,18 – 20 Another causal mechanism for fibri-
nogen involvement in atherosclerosis is the promotion
of endothelial damage and diffuse intimal thickening
early during the disease’s course.10 Putting these
findings together, it seems reasonable to speculate
that fibrinogen levels potentially reflect the activity of
the atherosclerotic process and are a surrogate marker
for the individual’s risk for poor outcome. Previously
in cardiologic patients, elevated fibrinogen was
reported to increase the risk of short term mortality.12
Analysing mortality rates in the present study accord-
ing to the baseline fibrinogen level (Fig. 1), it becomes
obvious the Kaplan Meier curves markedly diverge
after 3–5 years, indicating that elevated fibrinogen
was mainly associated with increased long-term rather
than early mortality in this groups of high risk patients
with peripheral atherosclerosis.
Considering the prognostic impact of fibrinogen for
the occurrence of future cardiovascular or all-cause
mortality, one has to recognise that the effect size in
terms of the hazard ratios was rather small, suggesting
that this measurement adds little to risk prediction of
adverse events in clinical practice. However, patients
with atherosclerosis and hyperfibrinogenaemia may
be good candidates for treatment with fibrates, which
in contrast to statins combine lipid-lowering with
beneficial fibrinogen-lowering effects.21 Nevertheless,
it has to be acknowledged that statins have a larger
effect on the reduction of cardiovascular and all-cause
mortality22 and, therefore, should be used preferen-
tially or in controlled combination.
Remarkably, in the present patient series, smokers
and patients with hyperlipidemia exhibited reduced
mortality rates in univariate analysis. This may be
explained by an interaction with patients’ age, since
current smokers and hyperlipidemic patients were
significantly younger. Indeed, we found no significant
influence of these variables on outcome when adjust-
ing for patients’ age in the multivariate model. Patients
with diabetes mellitus, in contrast, had an increased
mortality during the follow up period. These patients
also had significantly higher fibrinogen levels at initial
presentation, presumably due to enhanced inflamma-
tory activity. Nevertheless, no effect modification was
observed testing for interaction between fibrinogen
and diabetes and both variables independently pre-
dicted patients’ mortality.
Limitations
We are aware of the limitations of a retrospective study
design. In a non-randomised setting it is very difficult
to account for the effects of changing medication
during a study period of 10 years. Certainly, the
increasing use of statins and ACE inhibitors during the
recent years may influence mortality rates of these
patients, but these data hardly can be acquired
retrospectively. However, due to the careful and
standardised patient evaluation with respect to cardi-
ovascular risk factors and the complete follow-up data
which were obtained via an independent institution,
the interpretation of our findings seem valid.
Conclusion
Elevated fibrinogen levels in patients with PAD
indicate an increased risk for poor outcome, particu-
larly for fatal cardiovascular complications. Patients
with hyperfibrinogenaemia, therefore, may be con-
sidered for close monitoring of cardiovascular comor-
bidities, aggressive treatment of concomitant risk
factors and potentially for fibrinogen-lowering thera-
peutic approaches.
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